Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mayne Pharma Group Limited
  6. News
  7. Summary
    MYX   AU000000MYX0

MAYNE PHARMA GROUP LIMITED

(MYX)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 10/27
0.34 AUD   +3.03%
10/19MAYNE PHARMA : 2021 Corporate Governance Statement and Appendix 4G
PU
10/07MITHRA PHARMACEUTICALS S A : Provides FDA Update on Myring
AQ
10/07MAYNE PHARMA : Provides fda update on generic nuvaringo
AQ
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mayne Pharma : 2021 Full Year Investor Presentation

08/27/2021 | 05:12am EDT

Mayne Pharma Group Limited

FY21 Results Presentation 27 August 2021

Scott Richards, CEO

Peter Paltoglou, CFO

Disclaimer

The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company's audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential investors.

Non-IFRS information

  • Other than as indicated, the financial information contained in this document is directly extracted or calculated from the audited Financial Statements. Throughout this document some non-IFRS financial information is stated, excluding certain specified income and expenses. Results excluding such items are considered by the Directors to provide a meaningful basis for comparison from period to period.
  • Earnings before interest, tax, depreciation and amortisation (EBITDA) - a non-IFRS term - is considered by Directors to be a meaningful measure of the operating earnings and performance of the Group and this information may be useful for investors.
  • The non-IFRS financial information has not been audited by the Group's auditors.

Forward looking statements

  • This presentation contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to the Company. These forward looking statements use words such as 'potential', 'expect', 'anticipate', 'intend', 'plan' and 'may', and other words of similar meaning. No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including the Company). Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Given these uncertainties, readers are cautioned not to place undue reliance on such forward looking statements. Subject to the Company's continuous disclosure obligations at law and under the listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward looking statements. The factors that may affect the Company's future performance include, among others: changes in economic conditions, changes in the legal and regulatory regimes in which the Company operates, litigation or government investigations, decisions by regulatory authorities, changes in behaviour of major customers, suppliers and competitors, interruptions to manufacturing or distribution, the success of research and development activities and research collaborations and the Company's ability to protect its intellectual property.

Other

2

Business and strategy update

Operating momentum through a challenging year1

A$401m

A$66m

A$75m

A$26m

reported sales

reported EBITDA

underlying EBITDA2

opex2 reduction

(-3% YOY in

(-5% YOY in

(-10% YOY in

(-13% YOY in constant

constant currency)

constant currency)

constant currency)

currency)

1

80

11

70

'first pass' NDA

personnel added

dermatology and

active third party

approval for

to new US

women's health

contract development

NEXTSTELLIS®

women's health

products added

projects globally

team

to portfolio

(+17% YOY)

targeting

US$650m in

IQVIA sales3

1. FX had adverse impact on earnings with the average AUD:USD rate of 0.747 in FY21 v 0.671 in FY20

4

2. Excludes NEXTSTELLIS® set up costs

3. IQVIA, MAT Sales, June 2021

Achieved strategic rebalance of the business to more sustainable categories

Gross profit by type1

FY19

FY21

18%

27%

29%

44%

9%

10%

16%

26%

5%

14%

2%

56%

82%

Dermatology

Women's health

Infectious disease

US Contract Services

International

US retail generic

1. Reported gross profit adjusted for the internal manufacturing margin on US products included in US Contract Services and International in both periods

5

Disclaimer

Mayne Pharma Group Limited published this content on 27 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 August 2021 09:11:05 UTC.


ę Publicnow 2021
All news about MAYNE PHARMA GROUP LIMITED
10/19MAYNE PHARMA : 2021 Corporate Governance Statement and Appendix 4G
PU
10/07MITHRA PHARMACEUTICALS S A : Provides FDA Update on Myring
AQ
10/07MAYNE PHARMA : Provides fda update on generic nuvaringo
AQ
10/06MAYNE PHARMA : to Address US FDA Feedback on Generic Version of Birth Control Product
MT
10/06MAYNE PHARMA : 07/10/2021áMayne Pharma provides FDA update on generic NUVARING
PU
10/06Mayne Pharma Provides US Food and Drug Administration Update on Generic NUVARING
CI
10/05MITHRA PHARMACEUTICALS S A : Announces the Appointment of its Representative to Mayne Phar..
AQ
10/04MAYNE PHARMA : appoints new Director
PU
10/03Mayne Pharma Group Limited Appoints Carolyn Myers to the Board
CI
09/30MAYNE PHARMA : Upsher-Smith Launches Three Additional Strengths of Isotretinoin Capsules
AQ
More news
Financials
Sales 2022 461 M 346 M 346 M
Net income 2022 -26,7 M -20,1 M -20,1 M
Net Debt 2022 257 M 193 M 193 M
P/E ratio 2022 -17,6x
Yield 2022 -
Capitalization 600 M 451 M 451 M
EV / Sales 2022 1,86x
EV / Sales 2023 1,52x
Nbr of Employees 967
Free-Float 77,2%
Chart MAYNE PHARMA GROUP LIMITED
Duration : Period :
Mayne Pharma Group Limited Technical Analysis Chart | MYX | AU000000MYX0 | MarketScreener
Technical analysis trends MAYNE PHARMA GROUP LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 0,34 AUD
Average target price 0,45 AUD
Spread / Average Target 31,5%
EPS Revisions
Managers and Directors
Scott Richards Chief Executive Officer, MD & Executive Director
Peter Paltoglou Chief Financial Officer
Frank C. Condella Chairman
Gerard G. Nahum Chief Medical Officer
Keith Moore Vice President-Research & Development